The role of cetuximab as first-line treatment of colorectal liver metastases
about
Colorectal cancer cells are resistant to anti-EGFR monoclonal antibody through adapted autophagy.Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases.Anti-EGFR antibody sensitizes colorectal cancer stem-like cells to Fluorouracil-induced apoptosis by affecting autophagy.Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients.
P2860
The role of cetuximab as first-line treatment of colorectal liver metastases
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The role of cetuximab as first-line treatment of colorectal liver metastases
@ast
The role of cetuximab as first-line treatment of colorectal liver metastases
@en
type
label
The role of cetuximab as first-line treatment of colorectal liver metastases
@ast
The role of cetuximab as first-line treatment of colorectal liver metastases
@en
prefLabel
The role of cetuximab as first-line treatment of colorectal liver metastases
@ast
The role of cetuximab as first-line treatment of colorectal liver metastases
@en
P2093
P2860
P1476
The role of cetuximab as first-line treatment of colorectal liver metastases
@en
P2093
Billy McWilliams
Claire Jones
Mark A Taylor
P2860
P356
10.1111/J.1477-2574.2012.00591.X
P577
2012-10-17T00:00:00Z